Stock NAMS NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NewAmsterdam Pharma Company N.V. Nasdaq

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
19.75 USD +0.41% Intraday chart for NewAmsterdam Pharma Company N.V. +15.43% +76.81%
11/06 NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043 MT
10/06 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 - 830.7 833.1 1,664 - -
Enterprise Value (EV) 1 - 392.2 833.1 1,664 1,664 1,664
P/E ratio -3.39 x -10.6 x -5.1 x -7.91 x -12.3 x -12.7 x
Yield - - - - - -
Capitalization / Revenue - 8.52 x 64.1 x 193 x 264 x 106 x
EV / Revenue - 8.52 x 64.1 x 193 x 264 x 106 x
EV / EBITDA - - - - - -
EV / FCF - 104 x -6.39 x -9.42 x -13.2 x -11.6 x
FCF Yield - 0.96% -15.6% -10.6% -7.56% -8.61%
Price to Book - 1.71 x - - - -
Nbr of stocks (in thousands) - 81,560 82,324 89,986 - -
Reference price 2 8.575 10.19 10.12 18.49 18.49 18.49
Announcement Date 04/08/22 31/03/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 97.5 13.01 8.638 6.311 15.7
EBITDA - - - - - -
EBIT 1 - -6.96 -168.9 -187.3 -158.4 -160.6
Operating Margin - -7.14% -1,298.56% -2,168.39% -2,509.28% -1,022.79%
Earnings before Tax (EBT) 1 - -78.05 -163.3 -207.2 -136.1 -141.4
Net income 1 -28.6 -78.05 -163.3 -209.9 -139.1 -140.2
Net margin - -80.05% -1,255.76% -2,429.54% -2,204.4% -892.77%
EPS 2 -2.530 -0.9600 -1.984 -2.337 -1.502 -1.457
Free Cash Flow 1 - 7.959 -130.4 -176.6 -125.7 -143.3
FCF margin - 8.16% -1,002.43% -2,044.09% -1,991.99% -912.42%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 04/08/22 31/03/23 28/02/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S2 2023 S1 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4 9.562 1.304 1.11 1.843 4.557 - -
EBITDA - - - - - - - -
EBIT 1 - - -51.63 -50.53 -45.77 -39.57 -41.86 -37.26
Operating Margin - - -3,960.17% -4,551.36% -2,483.95% -868.24% - -
Earnings before Tax (EBT) 1 - - -93.77 -47.56 -41.99 -37.21 -38.47 -33.85
Net income 1 - -75.1 -93.77 -48.33 -42.33 -37.74 -38.47 -33.85
Net margin - -785.42% -7,192.76% -4,353.34% -2,297.1% -828.09% - -
EPS 2 - -0.9200 -0.9863 -0.5394 -0.4679 -0.4150 -0.3950 -0.3488
Dividend per Share - - - - - - - -
Announcement Date 31/03/23 07/08/23 08/05/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - 439 - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - 7.96 -130 -177 -126 -143
ROE (net income / shareholders' equity) - -29.2% - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 5.940 - - - -
Cash Flow per Share - 0.1000 - - - -
Capex 1 - 0.01 0.02 0.92 1.85 2.77
Capex / Sales - 0.01% 0.17% 10.7% 29.3% 17.66%
Announcement Date 04/08/22 31/03/23 28/02/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for NewAmsterdam Pharma Company N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.49 EUR
Average target price
35.19 EUR
Spread / Average Target
+90.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 116B
ARGENX SE Stock argenx SE
+22.18% 27.03B
BIONTECH SE Stock BioNTech SE
-21.81% 20.36B
GENMAB A/S Stock Genmab A/S
-16.89% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.91B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.59B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. NAMS Stock
  5. Financials NewAmsterdam Pharma Company N.V.